Azenta cuts FY2026 outlook; Q2 loss per share $3.41 includes $149 million charge
Azenta reported fiscal second-quarter 2026 revenue of $145 million, up 1% year over year, but organic revenue fell 3% and the company recorded a $149 million non-cash goodwill impairment, producing a diluted loss of $3.41 per share from continuing operations. Azenta also lowered its fiscal 2026 guidance, now expecting organic revenue of down about 2% to up 1% versus prior growth of 3% to 5%, and extended its long-range plan to 2029. The $63 million sale of B Medical Systems has not closed because the buyer has not secured financing.
Key points
- Q2 revenue was $145 million, up 1% year over year; organic revenue declined 3%
- Diluted EPS from continuing operations was ($3.41) versus ($0.43) a year earlier, including a $149 million goodwill impairment
- FY2026 organic revenue now expected to range from down about 2% to up 1%, versus prior guidance of 3% to 5% growth
- Adjusted EBITDA margin now expected to fall about 125 basis points to flat; B Medical Systems $63 million sale did not close by March 31, 2026
The filing
Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.